Equine/Horse Arteritis Virus N proteins antibody and antigen (recombinant protein)

 Download 

Diagnostic anti-Equine/Horse Arteritis Virus N proteins antibodies pairs and antigen for animal health (animal Equine/Horse infectious disease Equine/Horse Viral Arteritis) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Go to Equine/Horse disease testing products collection >>

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-VT-P142-Tg004-Ag01	Recombinant Equine/Horse Arteritis Virus N proteins protein	$3090.00
GMP-VT-P142-Tg004-Ab01	Anti-Equine/Horse Arteritis Virus N proteins mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P142-Tg004-Ab02	Anti-Equine/Horse Arteritis Virus N proteins mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P142-Tg004-Ab03	Anti-Equine/Horse Arteritis Virus N proteins human monoclonal antibody (mAb)	$3090.00
GMP-VT-P142-Tg004-Ab04	Anti-Equine/Horse Arteritis Virus N proteins human monoclonal antibody (mAb)	$3090.00

Size： 1mg | 10mg | 100mg

Product Description

Cat No.	GMP-VT-P142-Tg004-Ag01
Product Name	Recombinant Equine/Horse Arteritis Virus N proteins protein
Pathogen	Equine/Horse Arteritis Virus
Expression platform	E.coli
Isotypes	Recombinant Antigen
Bioactivity validation	Anti-Equine/Horse Arteritis Virus N proteins antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Equine/Horse Arteritis Virus level test of animal Equine/Horse infectious disease with Equine/Horse Viral Arteritis.
Tag	His
Product description	Recombinant Equine/Horse Arteritis Virus N proteins proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P142-Tg004-Ab01,GMP-VT-P142-Tg004-Ab02
Pathogen	Equine/Horse Arteritis Virus
Product Name	Anti-Equine/Horse Arteritis Virus N proteins mouse monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Recombinant Equine/Horse Arteritis Virus N proteins antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine/Horse Arteritis Virus antibodies in Equine/Horse Arteritis Virus level test of animal Equine/Horse infectious disease with Equine/Horse Viral Arteritis.
Product description	Anti-Equine/Horse Arteritis Virus N proteins mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine/Horse Arteritis Virus antibodies.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P142-Tg004-Ab03,GMP-VT-P142-Tg004-Ab04
Pathogen	Equine/Horse Arteritis Virus
Product Name	Anti-Equine/Horse Arteritis Virus N proteins human monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Human lgG1
Bioactivity validation	Recombinant Equine/Horse Arteritis Virus N proteins antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine/Horse Arteritis Virus antibodies in Equine/Horse Arteritis Virus level test of animal Equine/Horse infectious disease with Equine/Horse Viral Arteritis.
Product description	Anti-Equine/Horse Arteritis Virus N proteins mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Pathogen Information

Equine/Horse Arteritis Virus (EAV) is a significant viral pathogen that causes disease primarily in horses. It is responsible for the development of equine arteritis, which leads to the respiratory and reproductive tract problems in horses. It is a positive-sense, single-stranded RNA virus belonging to the family Arteriviridae within the order Nidovirales. Other members of the same family include porcine reproductive and respiratory syndrome virus (PRRSV), lactate dehydrogenase-elevating virus (LDV), simian hemorrhagic fever virus (SHFV), and murine hepatitis virus (MHV), among others. EAV is an enveloped virus, with a genome size of approximately 14 kilobases.

The EAV genome has at least fifteen virally encoded proteins that are essential for its replication and pathogenesis. Some of these proteins, including nucleocapsid protein (N), glycoprotein (GP), membrane protein (M), and other non-structural proteins, have been extensively studied. The N protein binds to viral RNA to form the helical nucleocapsid, while GP5 forms spikes on the viral surface. M protein plays an important role in virus assembly and budding.

EAV mostly infects horses; however, it can also infect donkeys and zebras. Infection usually occurs through inhalation of aerosolized secretions or direct contact with infected animals. Once ingested, the virus replicates in the respiratory and intestinal epithelium, leading to systemic spread. Clinical signs of EAV infection usually occur between 4 to 14 days post-infection and may include fever, lethargy, and nasal discharge. Infections are often subclinical, where horses may be infected but show no signs of illness. However, in some cases, the infection can result in severe respiratory and reproductive issues, including abortion in pregnant mares, severe pneumonia, and thrombosis.

Diagnostic tests for EAV infection are critical to controlling outbreaks and preventing the spread of the virus. Serological techniques, including virus neutralization assays, indirect fluorescent antibody tests (IFATs), and enzyme-linked immunosorbent assays (ELISAs), are commonly used to diagnose EAV. These tests detect the presence of antibodies produced by the host's immune system in response to the viral infection. Molecular tests, such as reverse transcription-polymerase chain reaction (RT-PCR) and real-time RT-PCR, are also used for EAV diagnosis. These tests target highly conserved genes such as N, M, or GP5 for the detection of viral RNA.

The prevention of EAV infection is primarily through vaccination. The vaccines for EAV vary widely in their composition, but all are aimed at eliciting an immune response that can prevent disease and limit the spread of infection. Vaccines are administered either intramuscularly or intranasally, and booster doses are recommended to maintain protection. However, there is no specific treatment for EAV; supportive care is essential in managing the clinical signs of infection, as well as the secondary bacterial infections that may arise.

In conclusion, EAV is a significant pathogen that can cause respiratory and reproductive issues in horses, donkeys, and zebras. The virus is highly contagious, and careful management of outbreaks is necessary to control its spread. Diagnostic tests for EAV infection are critical, and effective vaccines are available for prevention. As research continues, further understanding of EAV's biology and pathogenesis will lead to improved diagnostics, treatment, and control measures.

About GDU